Uncontrolled persistent allergic asthma in practice: eXpeRience registry baseline characteristics

Curr Med Res Opin. 2011 Apr;27(4):761-7. doi: 10.1185/03007995.2011.557717.


Background: Medical registries can be used to assess and monitor the effectiveness and safety of approved therapy, and provide insights into how quality of care can be optimized.

Methods: The post-marketing, non-interventional, observational registry (eXpeRience) aims to collect data on the treatment effectiveness and safety of omalizumab in 'real-world' practice. The baseline characteristics of patients with uncontrolled allergic asthma receiving omalizumab therapy and included in the first interim analysis of this observational registry are reported.

Results: A total of 294 patients were included in the first interim analysis. Of these patients, 271 (92.2%) were active in the registry at the time of reporting. At baseline, the mean duration of allergic asthma was approximately 19 years, with over 87% of patients testing positive for a perennial allergen. Mean % predicted FEV(1) and serum total IgE levels were 62.4% and 316.7 IU/mL, respectively. Asthma was uncontrolled for approximately 62% of patients, while around 23% were partly controlled. The majority of patients were being treated with multiple asthma controller medications, including inhaled-corticosteroids, long-acting β(2)-agonists and leukotriene receptor antagonists, and 28% of patients were also receiving maintenance oral corticosteroids. Concomitant diseases were present in many patients, the most common being perennial allergic rhinitis (42.5%).

Conclusions: Demographic and disease characteristics highlight the unmet clinical need in patients with uncontrolled allergic asthma. Future analyses from this study will further determine the real-life effectiveness and safety of omalizumab.

Publication types

  • Evaluation Study
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Asthmatic Agents / therapeutic use
  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Asthma / complications
  • Asthma / epidemiology
  • Asthma / therapy*
  • Child
  • Female
  • Humans
  • Hypersensitivity / complications
  • Hypersensitivity / epidemiology
  • Hypersensitivity / therapy*
  • Male
  • Middle Aged
  • Omalizumab
  • Professional Practice / statistics & numerical data*
  • Quality of Life
  • Registries / statistics & numerical data*
  • Retrospective Studies
  • Surveys and Questionnaires
  • Treatment Failure
  • Young Adult


  • Anti-Asthmatic Agents
  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Omalizumab